Startups

Edit

TVM Life Science Ventures VII

http://tvmlifescience.de/

Last activity: 20.07.2023

Probably Closed

Mentions

16

Mentions in press and media 16

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jan 13, 2022	Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies	Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA. Auricula Biosciences plans to develop a first-in-cl...
Nov 16, 2021	Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases	Luxembourg, November 15th, 2021 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing T7 Therapeutics, Inc., a company based in Wilmington, Delaware, USA. T7 Therapeutics plans to develop, a first-in-class mono...
Mar 4, 2019	Emovi is accelerating its growth through a 15M$ Series C investment led by TVM Capital Life Science	Photo: Emovi MONTREAL, March 4, 2019 /CNW Telbec/ – Emovi announced today its partnership with TVM Capital Life Science and co-investors StandUp Ventures and Desjardins Capital to support its global commercial activities. This 15M$ Series ...
Jan 2, 2019	Please use our dedicated page for Funding Requests!	We have added a new page to the website to ensure timely processing of your funding requests. Please use this dedicated page to file your deals with us: http://tvmlifescience.de/funding-request/
Sep 20, 2017	TVM Capital Life Science hosts its 6th annual Life Science Conference in Montreal	Montreal, September 19, 2017 TVM Capital Life Science convened its 6th annual Autumn Conference in Montreal yesterday, with more than 200 international attendees from Asia, the United States, Europe and Canada who networked with senior dec...
Jun 13, 2017	CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine	Rostock/Berlin, 13.06.2017 – CENTOGENE AG, a worldwide leader in the field of genetic diagnostics for rare diseases, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deuts...
Dec 7, 2016	Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS	Schlieren, Switzerland, and Munich, Germany, December 07, 2016 / B3C newswire / — Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in S...
Dec 5, 2016	Pfizer Ventures and TVM Life Science Ventures VII Announce Additional Investment in Ixchelsis Ltd.	London, UK, December 05, 2016 / — Pfizer Venture Investments (PVI) and TVM Life Science Ventures VII today announced that they are making an additional $12M investment in Ixchelsis Ltd, a start-up company based at Discovery Park, Sandwich, ...
Sep 19, 2016	TVM Life Science Ventures VII Announces Investment in AurKa Pharma Inc.	Montréal, Québec, September 19th, 2016 –TVM Life Science Ventures VII today announced the fund’s twelfth investment establishing AurKa Pharma Inc., a company based in Montréal, Québec. AurKa Pharma Inc. plans to develop, to proof-of-concept...
Jul 25, 2016	FDA grants QIDP and Fast Track Designations to MCB3837, Morphochem’s novel intravenous antibacterial to treat C. difficile infections	Munich (Germany), July 25, 2016 — Morphochem, a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as ...
Jun 22, 2016	Morphochem’s Investigational New Drug (IND) application accepted by the FDA – Novel antibacterial for intravenous treatment of Clostridium difficile infections (CDI), MCB3837/MCB3681, can now move into Phase 2	Munich, Germany, June 22, 2016 — Morphochem, a private clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for the company’s nov...
Apr 14, 2016	Esperas Pharma Inc. will begin clinical development of a new anti-cancer product at major Montreal hospitals	Montréal, Québec, April 11 2016 – Esperas Pharma Inc. (“Esperas”) today announced the initiation of a project to develop a new oral anticancer agent called ESP-01, in partnership with Quebec Clinical Research Organization in Cancer (Q-CROC)...
Dec 2, 2013	TVM Capital Life Science enters into Collaboration with Hanwha Biologics	Montreal/Seoul, December 2, 2013 – TVM Capital Life Science and Hanwha Chemical Corporation Biologics Business Unit (“Hanwha Biologics”) announced today that both parties entered into a global collaboration agreement. TVM Capital Life Scien...
Nov 4, 2013	TVM Capital to focus on Life Science Venture and Healthcare Private Equity Investing only	Two independent investment teams to focus on Life Science Venture Capital investments in Western Europe and North America and on Healthcare Private Equity investments in the MENA region Vienna, 04.November 2013 – During BioEurope 2013 in V...
May 28, 2012	Dr. Hubert Birner promoted to Managing Partner in the Wake of Opening of Montreal Office; Dr. Luc Marengere and Dr. Cynthia Lavoie join as senior partners	Munich-Montreal, 28 May 2012 – The TVM Capital Life Science Venture Practice announced start of operations of its new Montreal investment office and appointed Dr. Hubert Birner to Managing Partner. TVM Capital Life Science also has won two ...

Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about TVM Life Science Ventures VII

What has the press written about TVM Life Science Ventures VII?

Parsers VC has collected 16 articles mentioning TVM Life Science Ventures VII, among them “Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies” (Jan 13, 2022) and “Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases” (Nov 16, 2021).

Is TVM Life Science Ventures VII still active?

TVM Life Science Ventures VII is probably closed: its latest activity on Parsers VC dates from Jul 20, 2023.